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Phat is the Prognostic Value of
yocardial Perfusion Imaging Using
ubidium-82 Positron Emission Tomography?
eiichiro Yoshinaga, MD, Benjamin J. W. Chow, MD, Kathryn Williams, MS, Li Chen, MSC,
obert A. deKemp, PHD, Linda Garrard, RN, BSCN, Alexander Lok-Tin Szeto, MD, May Aung, RT,
oss A. Davies, MD, Terrence D. Ruddy, MD, Rob S. B. Beanlands, MD
ttawa, Ontario, Canada
OBJECTIVES The objective was to determine the prognostic value of rubidium-82 (82Rb) positron emission
tomography (PET) myocardial perfusion imaging (MPI).
BACKGROUND 82Rb PET MPI accurately diagnoses coronary artery disease (CAD). However, there are
limited data evaluating its prognostic value.
METHODS Follow-up (3.1  0.9 years) was obtained in 367 patients who underwent dipyridamole
82Rb PET MPI. Patients were divided into groups based on their summed stress score
(SSS): group I, normal (4); group II, mild (4 to 7); and group III, moderate (8 to 11) to
severe (12).
RESULTS There were significant differences among patients in the 3 SSS groups for hard events (cardiac
death and myocardial infarction [MI]) (p  0.001) and total cardiac events (hard events,
revascularization and hospitalization) (p  0.001). The annual hard events rates were 0.4%,
2.3%, and 7.0% in the normal, mild, and moderate-severe groups, respectively. In adjusted
survival models, 82Rb PET SSS was the strongest predictor of total cardiac events and a
significant predictor of hard events. Among patients referred for PET after 99mTc single-
photon emission computed tomography, the annual total event rate was higher with abnormal
versus normal SSS on PET (15.2% vs. 1.3%, p  0.001). In patients with obesity, the annual
total event rate was 11.1% with an abnormal scan and 1.5% with a normal scan (p  0.001).
CONCLUSIONS This study shows that 82Rb PET MPI has significant prognostic value for predicting cardiac
events, including death and MI. It also seems to have prognostic value in patients whose
diagnosis remains uncertain after single-photon emission computed tomography MPI and in
obese patients. The prognostic value of PET MPI may improve the management of cardiac
patients. (J Am Coll Cardiol 2006;48:1029–39) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.025Cardiology Foundation
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misk stratification of patients with suspected or documented
oronary artery disease (CAD) identifies patients at risk for
uture cardiac events. Myocardial perfusion imaging (MPI)
sing single-photon emission tomography (SPECT) has
hown good prognostic value (1–4), and patients with a
ormal SPECT MPI have a low hard cardiac events rate
1%/year) (5–7).
Positron emission tomography (PET) MPI has been
idely used as an accurate means to diagnose CAD (8–14).
ubidium-82 (82Rb) is a PET perfusion tracer produced
rom a strontium-82 (82Sr)/82Rb generator and is widely
sed in centers without immediate access to a cyclotron
9,11,13–16). Rubidium-82 PETMPI is highly specific and
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006, accepted March 7, 2006.ensitive for the diagnosis of CAD (11,13,14,17–19). How-
ver, data supporting the prognostic value of 82Rb PET
PI are limited (20). The primary goal of the current study
as to evaluate the prognostic value of 82Rb PET imaging
or the prediction of cardiac events.
Although SPECT MPI is a highly useful noninvasive
iagnostic modality for the detection of CAD, clinicians are
ometimes faced with equivocal or nondiagnostic results.
atients with equivocal scans have increased risk compared
ith a normal population (21). Further risk stratification of
hese patients is often required. Rubidium-82 PET MPI
ay be clinically useful for this indication (22). However,
ata to support this approach are in fact quite limited, and
o studies have evaluated the prognostic value of PET MPI
n such patients. A secondary objective of this study was to
valuate the prognostic value of 82Rb PET MPI among a
ubset of patients referred for 82Rb PET imaging after
PECT perfusion imaging.
The prevalence of obesity (body mass index [BMI] 30
g/m2) has dramatically increased since 1990 with 20% of
he U.S. adult population being reported as obese (23,24).
besity has a significant adverse impact on cardiovascular
orbidity (25,26). Obese patients require accurate diagnos-ic tools for the evaluation of their cardiac risk. Current
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Prognostic Value of 82Rb PET September 5, 2006:1029–39odalities often have diagnostic difficulties in the obese
opulation (27–30). Although PET MPI is often applied in
atients with obesity, its prognostic value in this population
as not been well studied. An additional secondary objective
f the current study was to evaluate the prognostic value of
2Rb PET MPI in a subset of patients with obesity.
ETHODS
tudy population. The study population was composed of
48 consecutive adult patients (age 18 years old) who
nderwent dipyridamole stress 82Rb PET MPI between
anuary 1, 2000, and October 31, 2000, at the University of
ttawa Heart Institute. Patients with known nonischemic
ardiomyopathy or significant valvular heart disease were
xcluded. Of the 448 patients, 37 (8.3%) patients were lost
o follow-up and 33 (7.4%) patients, although contacted,
eclined to participate in the follow-up study. The remain-
ng 378 patients were enrolled in the study.
Because abnormal scans can result in early revasculariza-
ion and potentially alter outcome, 11 (2.9%) patients with
arly revascularization (in the first 3 months after 82Rb PET
PI) were excluded from the prognostic portion of the
nalysis. Similar approaches have been applied in previous
tudies (2,3,31,32). Thus, the prognostic data presented in
he current study are based on a population of 367 patients.
The study was approved by the University of Ottawa
eart Institute Human Research Ethics Board. Informed
onsent was obtained from all subjects. In cases in which
atients died before follow-up, consent was obtained from
he next of kin.
ET acquisition protocol. Patients were positioned in a
hole-body PET scanner (ECAT ART, Siemens/CTI
noxville, Tennessee), a 4-min transmission scan was per-
ormed for attenuation correction (33). Immediately after
he transmission scan, 400 to 2000 MBq (8 MBq/kg) of
2Rb was administered intravenously over 1 min. A 7.5-min
cquisition was initiated 2.5 min after tracer administration
14,33–36).
ipyridamole myocardial perfusion 82Rb PET imag-
ng. Patients were instructed to fast for6 h and to abstain
Abbreviations and Acronyms
BMI  body mass index
CABG  coronary artery bypass grafting
CAD  coronary artery disease
MI  myocardial infarction
MPI  myocardial perfusion imaging
PCI  percutaneous coronary intervention
PET  positron emission tomography
82Rb  rubidium-82
SDS  summed difference score
SPECT  single-photon emission computed tomography
SRS  summed rest score
SSS  summed stress scorerom caffeine-containing products for 12 h before phar- bacological stress. After the rest 82Rb PET imaging, a phar-
acological stress test was performed with the infusion of
ipyridamole (0.14 mg/kg/min over 5 min). Stress imaging
as acquired using the identical protocol as the rest imaging.
he 82Rb (400 to 2,000 MBq [8 MBq/kg]) was infused 3
in after completion of the dipyridamole infusion
33,35,36). During dipyridamole stress, symptoms, heart
ate, blood pressure, and the electrocardiogram were mon-
tored continuously.
ET image interpretation. Regional myocardial perfusion
as assessed using the 17-segment model recommended by
he Cardiac Imaging Committee of the American Heart
ssociation and the American Society of Nuclear Cardiology
36,37). Each segment was scored by two expert observers
linded to clinical data using a five-point scoring system (0 
ormal, 1  mildly reduced, 2  moderately reduced, 3 
everely reduced, 4  absent uptake) (36,38,39). Differences
etween observers were settled by a third observer. The sum of
egment scores at stress (summed stress score [SSS]), scores at
est (summed rest score [SRS]), and differences between stress
nd rest score (summed difference score [SDS]) were calcu-
ated (4). Patients were divided into groups based on their
SS (3,4,14,21). Because we used a 17-segment model
ccording to American Society of Nuclear Cardiology rec-
mmendation (36), we adjusted the validated SPECT
0-segment model scoring to be equivalent percentages of
he total possible score in the myocardium. Thus, a scan was
onsidered normal if the SSS was 4, mildly abnormal if
SS was between 4 and 7, moderately abnormal if SSS was
etween 8 and 11, and severely abnormal if SSS was 12.
his normal/abnormal cutoff represents a similar percentage
f the myocardium used as a cutoff score in previous PET
tudies (14). The moderately abnormal and severely abnor-
al groups were combined because of the small number of
atients in the moderately abnormal group. The SSS was
he primary focus of our analysis.
Patients were also divided into groups based on their SDS
ombined with their SSS: patients with a SDS 2 were
onsidered to have myocardial ischemia; patients with an
DS2 with normal SSS were considered normal; patients
ith SDS 2 but abnormal SSS were considered to have
car without ischemia.
Image quality was evaluated by two experts blinded to
linical or other imaging data and scored on a three-point scale:
uboptimal 0 (artifact such that a definitive conclusion could
ot be made), fair  1 (an artifact but interpretation was
ade), good  2 (conclusive interpretation).
atient follow-up. Patient follow-up was performed using
scripted telephone interview by health care professionals
linded to the patient’s MPI data. The mean follow-up
eriod was 3.1  0.9 years. Cardiac events were confirmed
sing the best information that was available. Hard cardiac
vents were defined as either cardiac death (confirmed by
eview of death certificate, hospital chart, or physician’s
ecords) or nonfatal MI (considering the appropriate com-
ination of elevated cardiac enzymes, electrocardiogram
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September 5, 2006:1029–39 Prognostic Value of 82Rb PEThanges, and ischemic symptoms, from hospital chart or
hysician’s records). Late (3 months) revascularization
coronary artery bypass grafting [CABG] or percutaneous
oronary intervention [PCI]) or the need for other hospi-
alization for cardiac causes (e.g., unstable angina, chest
ain, heart failure) other than MI were defined as other
ardiac events. Hence total cardiac events were a composite
f cardiac death, nonfatal MI, late revascularization, and
ardiac hospitalization.
If the patients had hard cardiac events, patients in the
tudy only had one hard cardiac event, death or nonfatal MI.
or total cardiac events, some patients had two or more
vents (e.g., nonfatal MI and revascularization). In such
atients, the first event date was considered for the survival
nalysis.
ubgroup populations—patients referred for PET after
PECT MPI. To further evaluate the prognostic value of
2Rb PET MPI, we assessed the subgroup of patients with
ecent 99mTc SPECT MPI. The goal of this ancillary
ubgroup analysis was to evaluate the prognostic value of
2Rb PET MPI in cases of patients referred after SPECT,
n which uncertainty about the diagnosis remained either
ased on the SPECT report or in which SPECT findings
id not support the clinical impression. Clinical SPECT
PI reports were reviewed by two observers blinded to
2Rb PET imaging data to categorize SPECT image
ndings and image quality.
A subgroup of 102 patients was identified who had had
PECT MPI within 6 months before 82Rb PET MPI
tudies. Among these, one patient who had unstable angina
etween SPECT and 82Rb PET MPI was excluded. Two
atients had early revascularization. These two patients were
ncluded in image quality analysis but excluded from the
econdary outcome analysis. Five patients with thallium-
01 (201Tl) SPECT MPI were also excluded. In addition,
our patients had clear-cut moderate-severe abnormalities
n SPECT that had similar location, extent, and severity of
efect as their 82Rb PET MPI studies. These patients were
ncluded in the 99mTc SPECT versus 82Rb PET image
uality analysis but excluded from the secondary outcome
nalysis, so as not to bias the prognostic value data in favor
f PET. Therefore, the subgroup was composed of 96
atients for image quality and 90 patients for secondary
utcome analysis, who were referred for PET after 99mTc
PECT MPI.
Among these 96 patients, 50 patients had exercise; 45 had
ipyridamole stress 99mTc SPECT MPI, and 1 had rest
PECT imaging but did not get dipyridamole because of
ery poor image quality at rest, rendering the images
quivocal.
9mTc SPECT imaging. The SPECT MPI was per-
ormed at either the University of Ottawa Heart Institute
n  92) or other referring institutions (n  10). For 99mTc
PECT MPI studies, a same-day, rest-stress 99mTc tetro-
osmin or 99mTc sestamibi injection protocol was used. For
he rest studies, tomographic imaging was initiated 30 to 45 cin after 296 to 370 MBq of 99mTc tetrofosmin or 99mTc
estamibi tracer injection. The 99mTc tomographic images
ere obtained using a standard 30-min 180° SPECT
cquisition protocol (40).
The stress study was performed approximately 120 min
fter the rest imaging. For patients who underwent
ymptom-limited treadmill exercise using the Bruce proto-
ol, a dose of 925 to 1,110 MBq of 99mTc tetrofosmin or
9mTc sestamibi was injected at peak exercise and the
atients continued exercise for an additional 1 to 2 min. For
hose who underwent dipyridamole stress testing, 3 min
fter the completion of dipyridamole (0.14 mg/kg/min over
min), tracer was injected intravenously. Tomographic
maging was initiated 30 to 45 min after the tracer injection.
he same acquisition protocol for rest was used for stress
40). Based on clinical reports, a similar protocol was
ollowed for the patients referred from other institutes.
mage quality and diagnostic certainty with 99mTc
PECT and 82Rb PET MPI. All clinical SPECT reports
ere reviewed. Image quality was classified as described for
2Rb PET MPI; suboptimal  0, fair  1, good  2.
Regarding diagnostic certainty of the images, reports that
ere definitively indicated as normal or abnormal were
onsidered conclusive, whereas diagnostic uncertainty was
efined as studies in which reports were not conclusive and
ere considered to be probably normal, equivocal, or prob-
bly abnormal (41). Diagnostic certainty was scored as
onclusive  1 or uncertainty  0. A total of 96 patients
ere evaluated for image quality and diagnostic certainty
nalysis.
ETMPI in patients with obesity. There are limited data
n the value of MPI in patients with obesity (defined as
MI 30 kg/m2) (42); thus, we further evaluated the
rognostic value of PET MPI in this subgroup.
The mean BMI of our study population was 30.0 
4.3 kg/m2. There were 134 (36.5%) patients with BMI
30 kg/m2 (obese), 136 (37.1%) patients with BMI 25 to
9.9 kg/m2 (overweight), and 97 (26.4%) patients with a
MI 25 kg/m2 (normal). The subgroup population for
his ancillary analysis was the obese population (n  134).
tatistical analysis. Continuous measures are presented as
eans  SD. For the univariable analysis of differences,
ilcoxon rank sum tests were used for continuous mea-
ures. Categorical measures are presented as frequencies
ith percentages. Frequencies were compared using Fisher
xact tests for the univariable analysis.
The prognostic value of SSS for unadjusted as well as
djusted hard (cardiac death and MI) and total cardiac event
ates were assessed for the full population. All unadjusted
omparisons of event rates were based on survival analysis
og-rank tests. Annual event rates were calculated by divid-
ng the 3-year Kaplan-Meier event rates by 3.
For the risk-adjusted analysis, multivariable Cox propor-
ional hazard models were used to assess the independent
rognostic value of the SSS controlling for baseline patient
haracteristics and creating adjusted survival curves. To
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Prognostic Value of 82Rb PET September 5, 2006:1029–39revent overfitting of the model, the number of variables
onsidered for modeling were reduced by combining the
oronary risk factors (hyperlipidemia, hypertension, diabe-
es, smoking, family history of CAD) into one variable (2
oronary risk factors). Also to limit the number of variables,
he baseline variables that showed significance in the uni-
ariable analysis were considered individually with SSS in
he model. From this testing, for the hard cardiac events,
ge 65 years, history of MI, and known CAD met the
hreshold for entry of p  0.05. These variables were
onsidered together in the stepwise selection of the final
ultivariable model for hard cardiac events (cardiac death
nd MI), which included only three covariates (SSS, age
65 years, and history of MI). For total cardiac events,
en, history of MI and CABG, known CAD, angina
ymptoms, and patients with two or more coronary risk
actors met the threshold for entry of p  0.05. These
ariables were considered together in the stepwise selection
f the final multivariable model for total cardiac events,
hich included four covariates (SSS, gender [male], history
f MI, and two or more coronary risk factors).
The multivariable models with and without SSS were
roduced to determine the incremental value of SSS. A
tatistically significant increase in the global chi-square
alue of the models with SSS defined an incremental
rognostic value of SSS. The percent of contribution of each
ovariate to the global chi-square value was also reported to
how the relative importance of the variables in the hard
cardiac death and MI) and total cardiac events models.
For the secondary analyses of the subgroups populations,
he small number of events combined with the small sample
ize in the subgroups limited the ability to perform the
ultivariable analysis. Thus, only unadjusted survival anal-
sis was performed for these subpopulations.
The concordance between 82Rb PET and 99mTc SPECT
PI for classifying the image quality and diagnostic cer-
ainty was determined using kappa statistics. The mean
mage quality score was compared using the Wilcoxon
igned rank test. The comparison of diagnostic certainty of
he images (conclusive 1, uncertainty 0) was performed
sing the McNemar test.
A p value  0.05 was considered statistically significant.
tatistical calculations were carried out using SAS software
version 9.1.2, SAS Institute Inc., Cary, North Carolina).
ESULTS
atient characteristics. The baseline characteristics of the
67 patients who comprised the study population are shown
n Table 1. The characteristics of the patients who were lost
o follow-up were all similar to the study population (p 
S), including mean age (57.6  14.2 years), gender
40.5% male), and SSS distribution (normal, 26 [70.3%];
ild, 4 [10.8%]; moderate to severe, 7 [18.9%]).
utcome events. Among the 367 patients in this study,here were 11 (3.0%) cardiac deaths and 6 (1.6%) nonfatal sIs. A total of 29 (7.9%) patients underwent late revascu-
arization (PCI alone [n  19], CABG alone [n  8], or
oth PCI and CABG [n  2]). A total of 16 (4.4%)
atients were hospitalized for cardiac causes (other than
evascularization or MI). Fifty-nine patients (16.1%) suf-
ered a total of 62 cardiac events (2 patients had nonfatal MI
nd late revascularization and 1 patient had late revascular-
zation and cardiac death on greatly separated dates).
nivariable analysis of baseline demographics for cardiac
vents. The results of univariable analysis of baseline de-
ographics (not including PET parameters) are summa-
ized in Table 2. Patients with hard cardiac events (cardiac
eath and nonfatal MI) were older, were more often male,
nd had a greater history of MI or CABG, known CAD,
ngina symptoms, and diabetes mellitus. Patients with any
ardiac event were older, were more often male, and had a
reater history of MI, CABG, PCI, known CAD, angina
ymptoms, coronary risk factors (2 or more), diabetes
ellitus, and smoking.
tress perfusion 82Rb PET abnormalities and outcomes.
ardiac events during follow-up as a function of the SSS
everity are shown in Table 3. The rates of both hard
cardiac death and nonfatal MI) and total cardiac events
ncreased with increasing severity of SSS. The respective
nnual hard cardiac event rates were 0.4%, 2.3%, and 7.0%
n patients with: 1) normal, 2) mildly, and 3) moderate to
able 1. Baseline Patient Characteristics
Patients With Follow-Up
(n  367)
ge (yrs) 59.4  10.9
ender (male) 168 (45.8%)
eight (m) 1.7  0.1
eight (kg) 83.5  47.2
MI (kg/m2) 30.0  14.3
bese 134 (36.5%)
atient follow-up time (yrs) 3.1  0.9
istory of MI 113 (30.9%)
istory of CABG 45 (12.3%)
istory of PCI 74 (20.2%)
nown CAD 148 (40.3%)
ngina symptoms (CCS class 2) 184 (54.3%)
HF (NYHA functional class II) 20 (5.7%)
oronary risk factors
Hyperlipidemia 211 (58.0%)
Hypertension 187 (51.2%)
Diabetes mellitus 60 (16.4%)
Smoking 224 (63.5%)
Family history of CAD 164 (44.8%)
ummed stress score
Normal 259 (70.6%)
Mild 44 (12.0%)
Moderate 13 (3.5%)
Severe 51 (13.9%)
bese was defined as BMI 30 (kg/m2) (42). Data are presented as mean  SD or
umber (%) of patients.
BMI  body mass index; CABG  coronary bypass grafting; CAD  coronary
rtery disease; CCS  Canadian Cardiovascular Society; CHF  congestive heart
ailure; MI  myocardial infarction; NYHA  New York Heart Association; PCI 
ercutaneous coronary intervention.everely abnormal SSS on 82Rb PETMPI. The annual total
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September 5, 2006:1029–39 Prognostic Value of 82Rb PETardiac event rates were 1.7%, 12.9%, and 13.2%, respec-
ively. Unadjusted survival free of hard cardiac events
ncluding cardiac death and nonfatal MI were significantly
ifferent among the SSS groups (cardiac death, p  0.001;
I, p  0.002; hard cardiac events, p  0.001) (Table 3).
nadjusted survival free of any cardiac events was also
ignificantly different among the SSS groups (p  0.001)
Table 3).
ultivariable Cox models of risk-adjusted outcomes. The
esults of multivariable analysis for cardiac events to
ssess the independent prognostic value of the SSS score
ontrolling for baseline patient characteristics are sum-
arized in Table 4. The model including 82Rb PET SSS
howed its independent prognostic value for the hard
ardiac events (p  0.016) after controlling for the
ignificant covariates age 65 years and history of MI.
f these variables, the strongest predictors (based on
ontribution to the hard cardiac event model) were age
65 years and 82Rb PET SSS. Considering the models
ith and without SSS, the significant increase in global
hi-square for the SSS model showed the incremental
rognostic value of the 82Rb PET SSS.
The model including 82Rb PET SSS showed its
ndependent prognostic value for the total cardiac events
able 2. Baseline Patient Characteristics by Cardiac Death/Nonf
Death/Nonfa
Patients
With Event
(n  17)
Patien
With No
(n  3
ge 65 yrs 12 (70.6%) 99 (28.
ender (male) 13 (76.5%) 155 (44.
istory of MI 15 (88.2%) 98 (28.
istory of CABG 7 (41.2%) 38 (10.
istory of PCI 5 (29.4%) 69 (19.
nown CAD 16 (94.1%) 132 (37.
ngina symptoms 13 (81.3%) 171 (52.
HF 2 (13.3%) 18 (5.3
atients with 2 coronary risk factors 10 (58.8%) 149 (42.
Hyperlipidemia 6 (37.5%) 205 (58.
Hypertension 11 (64.7%) 176 (50.
Diabetes mellitus 8 (47.1%) 52 (14.
Smoking 14 (87.5%) 210 (62.
Family history of CAD 6 (35.3%) 158 (45.
bese 7 (41.2%) 127 (36.
Fisher exact test.
Abbreviations as in Table 1.
able 3. Cardiac Events Over the Follow-Up Period for Differen
n Death NFMI
Revasc
(Late) H
ormal 259 1 (0.4%) 2 (0.8%) 7 (2.7%) 5 (
ild 44 2 (4.6%) 0 (0.0%) 12 (27.3%) 4 (
oderate and severe 64 8 (12.5%) 4 (6.3%) 10 (15.6%) 7 (
og-rank test p value 0.001 0.002 0.001 
One patient had nonfatal myocardial infarction and late revascularization. †One p
nfarction and late revascularization.
AER  annual event rate; Hosp  hospitalization; NFMI  nonfatal myocardial infarp  0.001) after controlling for the significant covariates
en, history of MI, and two or more coronary risk
actors. Of these variables, the strongest predictor (based
n contribution to the total cardiac event model) was
2Rb PET SSS. The incremental prognostic value of
2Rb PET SSS was also shown by the total cardiac events
odels with and without SSS.
Adjusted survival curves illustrate that SSS groups
ere significantly different for hard cardiac events (car-
iac death and nonfatal MI) (Fig. 1A) and total cardiac
vents (Fig. 1B).
ncillary and subgroup analysis—myocardial ischemia
nd outcomes. The prognostic value of SDS at follow-up
s shown in Table 5. Patients were divided into three
roups: group I, normal (normal SDS and SSS); group II,
schemia (SDS 2); group III, scar without ischemia
SDS 2; abnormal SSS). The unadjusted survival free of
ard cardiac events (cardiac death and nonfatal MI) was
ignificantly different among patients with scar without
schemia (group III), those with ischemia (group II), and
hose with normal SSS and no ischemia (group I) (p 
.001 for hard cardiac events, p  0.001 for cardiac
eath). Ischemia-related events (nonfatal MI and late
evascularization) were significantly different among pa-
I and Total Cardiac Events
I Total Events
t
p Value*
Patients
With Event
(n  59)
Patients
With No Event
(n  308) p Value*
0.001 26 (44.1%) 85 (27.6%) 0.014
0.012 47 (79.7%) 121 (39.3%) 0.001
0.001 41 (69.5%) 72 (23.5%) 0.001
0.002 19 (32.2%) 26 (8.4%) 0.001
0.354 21 (36.2%) 53 (17.2%) 0.002
0.001 46 (78.0%) 102 (33.1%) 0.001
0.037 45 (79.0%) 139 (49.3%) 0.001
0.205 4 (7.1%) 16 (5.4%) 0.536
0.215 38 (64.4%) 121 (39.3%) 0.001
0.120 38 (65.5%) 173 (56.5%) 0.246
0.323 36 (61.0%) 151 (49.4%) 0.118
0.003 16 (27.1%) 44 (14.4%) 0.021
0.060 47 (83.9%) 177 (59.6%) 0.001
0.465 26 (44.1%) 138 (45.0%) 1.000
0.797 20 (33.9%) 114 (37.0%) 0.768
med Stress Scores
Death or
NFMI
Death or
NFMI AER Total Events
Total Events
AER
3 (1.2%) 0.4% 15 events in 14
patients (5.4%)*
1.7%
2 (4.6%) 2.3% 18 (40.9%) 12.9%
) 12 (18.8%) 7.0% 29 events in 27
patients (42.2%)†
13.2%
0.001 0.001
had late revascularization and cardiac death. One patient had nonfatal myocardialatal M
tal M
ts
Even
50)
3%)
3%)
1%)
9%)
8%)
7%)
9%)
%)
6%)
9%)
6%)
9%)
3%)
3%)
3%)t Sum
osp
1.9%)
9.1%)
10.9%
0.001
atientction; Revasc  revascularization.
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Prognostic Value of 82Rb PET September 5, 2006:1029–39ients with ischemia (group II), those with scar without
schemia (group III), and those with normal SSS and no
schemia (group I) (p  0.034 for MI, p  0.001 for late
evascularization).
able 4. Multivariable Cox Proportional Hazard Models for Card
ncremental Prognostic Value of Summed Stress Score
Model Variable
ardiac death/nonfatal MI
Baseline Age 65 yrs
History of MI
Baseline  SSS Age 65 yrs
History of MI
Summed stress score
otal cardiac events
Baseline Gender (male)
History of MI
Patients with 2 coronary risk facto
Baseline  SSS Gender (male)
History of MI
Patients with 2 coronary risk facto
Summed stress score
Significant increase in global chi-square (p  0.05). †Significant increase in global
SSS  summed stress score; other abbreviations as in Table 1.
igure 1. (A) Risk-adjusted survival, free from hard cardiac events (cardiac
eath and nonfatal myocardial infarction), as a function of summed stress0
core (SSS). (B) Risk-adjusted survival, free from any (total) cardiac events,
s a function of SSS.ncillary and subgroup analysis—patients referred for PET
fter SPECT MPI. PATIENT CHARACTERISTICS. We as-
essed the subgroup of patients with recent 99mTc SPECT
PI to determine the image quality and diagnostic cer-
ainty (n  96) and the prognostic value of 82Rb PET MPI
n  90) in patients referred after SPECT in whom
ncertainty about the diagnosis remained.
Compared with the main study cohort, the patients who
ere referred for PET after 99mTc SPECT were younger,
ad less history of revascularization, had less known CAD,
nd had less severe SSS compared with the total cohort (total
ohorts vs. SPECT patients: age, 59.4 10.9 vs. 56.6  9.8
ears [p  0.023]; history of CABG, 12.3% vs. 3.3% [p 
.012]; history of PCI, 20.2% vs. 5.6% [p  0.001]; known
AD, 40.3% vs. 23.3% [p  0.003]; SSS distribution [p 
.002], respectively). There was a trend for less history of
I (p  0.051).
These patients had high BMI similar to the total cohort.
here was no significant difference in gender between the
wo cohorts (gender [male], 45.8% vs. 48.8%, p  0.638).
here was also no significant difference in other parameters,
ncluding follow-up time, angina symptoms, chronic heart
ailure class, and coronary risk factors (p  NS).
MAGE QUALITY COMPARISON BETWEEN 99mTc SPECT AND
2Rb PET MPI. In this specific study population, the overall
oncordance of image quality between 99mTc SPECT and
2Rb PET MPI was 22% (21 of 96, kappa  0.02) (Table 6).
he image quality was superior in PET compared with
PECT. The mean quality score of PET was 1.94  0.24,
nd that of SPECT was 0.71  0.78 (p  0.001).
IAGNOSTIC CERTAINTY OF IMAGING COMPARISON. In
his specific study population, the overall concordance for
he diagnostic certainty of the images between 99mTc
PECT and 82Rb PET MPI was 22% (21 of 96, kappa 
eath/Nonfatal MI and Total Cardiac Events Showing the
p Value
Percent of Global
Chi-Square Value
Global Chi-Square
Value
0.006 32.8 23.06
0.001 59.8
0.011 22.5 28.73*
0.036 15.3
0.016 20.4
0.001 27.1 58.63
0.001 37.2
0.005 13.7
0.001 15.0 72.13†
0.027 6.8
0.006 10.3
0.001 16.2
uare value (p  0.001).iac D
rs
rs.01) (Table 6). The diagnostic certainty of the image
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September 5, 2006:1029–39 Prognostic Value of 82Rb PETconclusive versus uncertainty) was superior using PET
ompared with SPECT (p  0.001).
ARDIAC EVENTS IN PATIENTS REFERRED FOR PET AFTER
PECT MPI. Among the 90 patients included in the outcome
nalysis, 11 (12.2%) patients had an abnormal 82Rb PET
SS (8 mildly abnormal and 3 severely abnormal) and 79
atients had a normal SSS.
During follow-up, there were a total of 11 cardiac events:
nonfatal MI, 7 late revascularizations, and 3 cardiac
ospitalizations. One patient had both a nonfatal MI and
ate revascularization. Thus, 10 patients (11.1%) suffered at
east one cardiac event.
Among 11 patients with an abnormal 82Rb PET SSS,
patients had a cardiac event with a high annual total
ardiac event rate (15.2%), compared with 3 patients
uffering a cardiac event in those with normal 82Rb PET
PI, for an annual total cardiac event rate of 1.3%.
nadjusted survival free of any (total) cardiac events was
able 5. Cardiac Events Over the Follow-Up Period for Ischemi
n Death NFMI
Revasc
(Late) Ho
roup I 254 1 (0.4%) 2 (0.8%) 7 (2.8%) 5 (2.
No ischemia
Normal SSS
roup II 94 6 (6.4%) 4 (4.3%) 21 (22.3%) 8 (8.
Ischemia
roup III 19 4 (21.1%) 0 (0.0%) 1 (5.3%) 3 (15
No ischemia
Abnormal SSS
og-rank test p value 0.001 0.034 0.001 0.
One patient had nonfatal myocardial infarction and late revascularization. †One p
nfarction and late revascularization.
Abbreviations as in Tables 3 and 4.
able 6. Image Quality Comparison and Diagnostic Certainty
f Image Comparison Between 99mTc SPECT and
2Rb PET MPI
PET
SPECT
Suboptimal Fair Good
mage quality comparison
Suboptimal — — —
Fair 4 2 0
Good 43 28 19
PET
SPECT
Diagnostic
Uncertainty Normal Abnormal
iagnostic certainty of image
comparison
Diagnostic uncertainty — — —
Normal* 40 15 25
Abnormal 7 3 6
mage quality agreement: 21/96 (22%), kappa  0.02. Diagnostic certainty of image
greement: 21/96 (22%), kappa  0.01. *No significant defect (i.e., summed stress
core 4).
MPI  myocardial perfusion imaging; PET  positron emission tomography;
PECT  single photon emission tomography.
r
pignificantly different between normal and abnormal SSS
roups (p  0.001) (Fig. 2).
ROGNOSTIC VALUEOF PETMPI IN PATIENTSWITHOBESITY.
mong the 134 patients with obesity, 45 (33.6%) had an
bnormal 82Rb SSS (15 mildly abnormal, 8 moderately
bnormal, and 22 severely abnormal) and 89 patients had a
ormal SSS.
During follow-up, there were a total of 22 cardiac events:
cardiac deaths, 2 nonfatal MIs, 8 late revascularizations,
nd 7 cardiac hospitalizations occurred in 20 patients. In the
ubgroup of 134 obese patients, 45 patients with an abnor-
al SSS had 7 hard cardiac events, with a high annual hard
ardiac event rate (6.0%) compared with 0% in those with
ormal 82Rb PET MPI (Table 7). Unadjusted survival free
rom hard cardiac events was significantly different between
ormal and abnormal SSS groups (p  0.001).
Similarly, among 45 patients with an abnormal SSS, 18
otal cardiac events occurred in 16 patients, with a high
nnual total cardiac event rate (11.1%) compared with 4
otal cardiac events in those with normal 82Rb PET MPI,
or an annual total cardiac event rate of 1.5% (Table 7).
nadjusted survival free of any (total) cardiac events was
Summed Stress Score
Death or
NFMI
Death or
NFMI AER Total Events
Total Events
AER
3 (1.2%) 0.4% 15 events in 14 patients
(5.5%)*
1.7%
10 (10.6%) 4.2% 39 events in 37 patients
(39.4%)†
12.2%
4 (21.1%) 8.7% 8 (42.1%) 14.0%
0.001 0.001
had late revascularization and cardiac death. One patient had nonfatal myocardial
igure 2. Unadjusted survival, free from any (total) cardiac events, as a
unction of normal and abnormal summed stress score on positron emission
omography (PET) myocardial perfusion imaging (MPI) in patientsa and
sp
0%)
5%)
.8%)
001
atienteferred for PET after recent single-photon emission computed tomogra-
hy MPI.
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roups (p  0.001) (Fig. 3).
ISCUSSION
hese results show that in this population, the rates of both
ard cardiac events (death and nonfatal MI) and other
ardiac events increase with severity of 82Rb PET stress
PI results. Normal 82Rb PET MPI indicates an excellent
rognosis with an annual hard cardiac event rate of 0.4%.
ultivariable analysis indicates an independent prognostic
alue of the 82Rb PET SSS.
In subgroup analyses the data suggests that in patients
ith recent SPECT MPI and in those with obesity, 82Rb
ET MPI has prognostic value and is able to identify
igher-risk patients.
rognostic value of PET MPI. The PET MPI has high
patial and temporal resolution compared with other nuclear
maging techniques (11,16). It yields high sensitivity and
pecificity for the detection of CAD (11,18,19,43). How-
ver, data supporting the prognostic value of PET MPI are
imited.
One previous study by Marwick et al. (20) evaluated the
rognostic value of 82Rb PET MPI in a population com-
osed mostly of patients with known CAD (70%). They
howed that 82Rb PET defect severity was associated with
ardiac death and total events rates. Mortality rates for
ormal and abnormal defects were 0.9% per year and 4.3%
able 7. Cardiac Events in Obese Patients
n Death NFMI
Revasc
(Late) Hosp
ormal 89 0 (0.0%) 0 (0.0%) 1 (1.1%) 3 (3.4%)
bnormal 45 5 (11.1%) 2 (4.4%) 7 (15.6%) 4 (8.9%)
og-rank test
p value
0.001 0.025 0.001 0.135
One patient had late revascularization and cardiac death. One patient had nonfatal
Abbreviations as in Table 3.
igure 3. Unadjusted survival free from any (total) cardiac events as a
unction of normal and abnormal summed stress score on PET MPI in
2c
atients with obesity (body mass index 30 kg/m ). Abbreviations as in
igure 2.er year. Our current study supports the notion that cardiac
vents increase with the severity of 82Rb PET MPI SSS.
owever, the two studies differ in patient population and
vent rates. In the study by Marwick et al. (20), most of the
atients (70%) had CAD, a large number (22%) of patients
ad early revascularization, and normal perfusion on PET
PI was present in only 24%. In contrast, the current study,
1% of patients had normal stress perfusion and 2.9%
atients had early revascularization. Thus, Marwick et al.
20) studied a higher-risk population than did our current
tudy. This higher-risk population may not reflect the
atients for whom PET has been suggested to be most
seful and cost-effective, namely those with a low and
ntermediate pretest likelihood of CAD (44).
Our patient population more closely resembles recent
PECT study populations in which 20% to 50% of patients
ad known CAD (3,6,21,32,45,46) and early revasculariza-
ion rates of 7% (3). In the current study, 40% of patients
ere known to have CAD, which may explain the lower
vent rates and lower early revascularization rate compared
ith the study by Marwick et al. (20). Our data indicate that
he extent of 82Rb PET MPI SSS has prognostic value and
pplicability in a lower-risk patient population. Also of note,
he current study showed that in the adjusted survival
odels, 82Rb PET MPI SSS was the strongest predictor of
otal cardiac events and was also a significant predictor of
ard cardiac events.
Marwick et al. (20) reported that ischemia was not related
o cardiac death and total cardiac events, which they
ttributed to their high early revascularization rate (22%)
mong patients with ischemia. This high revascularization
ate made it more difficult to evaluate the prognostic value of
schemia on 82Rb PET MPI. In the present study, the
ardiac death rate was significantly higher in patients with
xed defects (scar) compared with patients with ischemia or
ormal scans. However, ischemic events (nonfatal MI and
ate revascularization) were greater among the ischemic
roup. The current data suggest that the extent of ischemia
s identified by 82Rb PET MPI may also provide useful
rognostic information.
We have recently reported a very low hard cardiac event
ate (0.2% over 27 months of follow-up; 0.09% per year) in
group of patients with 82Rb PET MPI clinically reported
s normal (47). This very low event rate differs from the
eath or
NFMI
Death or
NFMI AER Total Events
Total Events
AER
(0.0%) 0 4 (4.5%) 1.5%
(15.6%) 6.0% 18 events in 16 patients
(35.6%)*
11.1%
0.001 0.001
rdial infarction and late revascularization.D
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7urrent study and is attributed to: 1) a more strict definition
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September 5, 2006:1029–39 Prognostic Value of 82Rb PETf normal (based on clinical reports); 2) shorter follow-up;
nd 3) exclusion of patients with left bundle branch block or
entricular pacing, in the previous study. In addition to the
onger follow-up, broader inclusion criteria, and use of SSS,
he current study also evaluated the prognostic value of
bnormal SSS on PET MPI.
The current study also differs from previous work and is
nique because it evaluates the prognostic value in impor-
ant subgroups in which PET may have additional value,
amely in patients whose diagnosis remains uncertain after
PECT MPI and in patients with obesity.
rognostic value of SPECT MPI. The prognostic value
f exercise and pharmacological SPECT MPI has been well
stablished (5–7). Previous SPECT studies showed annual
ard event rates of 0.2% to 0.8% for a normal SPECT MPI
tudy (2,3,21). The demographics and SSS in the current
tudy are similar to those of previous SPECT studies
2,3,21). Also, the increasing event rate with worsening
efect size along with the excellent event free survival in
atients with normal PET MPI are consistent with those of
revious SPECT studies (2–4,21,45).
Previous SPECT MPI studies showed that cardiac death
s better predicted by extent of myocardial scar, whereas
yocardial ischemia seems to predict ischemic events
6,32,48). Similar findings were observed in the current
tudy for PET MPI.
rognostic value of PET in patients referred after SPECT
PI. An equivocal SPECT MPI study is an American
ollege of Cardiology/American Heart Association/
merican Society of Nuclear Cardiology guidelines Class 1
ndication for the use of PET MPI (22). This recommen-
ation was based on consensus given the advantages of PET
maging. However, studies evaluating this approach have
een limited. MacIntyre et al. (49) reported that patients
ho had false-negative 201Tl SPECT but true positive 82Rb
ET had a significant change in their treatment strategies.
owever, to our knowledge, there has been no previous
tudy evaluating the prognostic value of PET in the clinical
etting when the diagnosis remains uncertain after SPECT
PI. The importance of this group of patients has been
valuated by Berman et al. (21), who reported that an
quivocal SPECT study was associated with increased
ardiac events and thus these patients may require additional
isk stratification. In the current study, a subgroup of 90
atients whose diagnosis remained uncertain after 99mTc
PECT MPI was evaluated and had been referred for 82Rb
ET MPI. In this subgroup, the annual total cardiac event
ate was higher in patients with abnormal 82Rb PET MPI
SS than in those with normal PET MPI (15.2% vs. 1.3%).
nadjusted survival from total cardiac events was signifi-
antly different between normal and abnormal PET MPI
SS groups (p 0.001). This study provides data to support
he consensus opinion in the American College of Cardi-
logy/American Heart Association/American Society of
uclear Cardiology guidelines for PET MPI. Further
utcome studies in this population are required. fIn this specific subpopulation of the current study, the
mage quality concordance between 82Rb PET MPI and
9mTc SPECT MPI was poor. Image quality was superior
ith 82Rb PET compared with 99mTc SPECT MPI. In
hese selected patients, the added value of PET likely
eflects its accuracy and its ability to correct for attenuation.
ttenuation-corrected SPECT MPI is currently applied in
imited centers (50). New methods of attenuation correction
re being developed for both SPECT and PET. These may
urther improve diagnostic accuracy and prognostic value for
oth modalities. Further studies are needed to evaluate these
volving approaches.
rognostic value of PET in obesity. Accurate diagnostic
ools are required to evaluate the cardiac risk of obese
atients. However, standard myocardial imaging with
PECT MPI and echocardiography may have technical
ifficulties in some patients with obesity (27–30). In the
resent study, 82Rb PET MPI distinguished cardiac event
isk in obese patients with known or suspected CAD. The
nnual hard cardiac event rates were 0% in those with a
ormal SSS and 6.0% in those with an abnormal SSS,
ndicating low and high risk, respectively (5,7,51).
The high spatial resolution and attenuation correction of
ET help explain the current findings in the obese popu-
ation (11). The current study supports the clinical utility of
2Rb PET MPI in patients with obesity.
tudy limitations. In the present study, the total hard
vent rate was low, at 4.6% in the overall study population.
owever, this hard event rate is similar to previous SPECT
tudies, which range between 2.6% and 5.5% in patients
ith suspected or known CAD (3,21,45,46,52). Our sample
ize and number of hard cardiac events were smaller.
owever, these were sufficient to detect significant differ-
nces in hard and total cardiac event rates among 82Rb PET
PI SSS groups. Post-hoc sample size calculations showed
power 80% with the univariable unadjusted survival
nalysis log-rank test for these comparisons.
The multivariable Cox proportional hazard models are
imited by the number of events. Accordingly, to prevent
verfitting of the multivariable Cox proportional hazard
odels, we reduced the number of variables entered into the
odel as described in the statistical methods section. With
he adjusted model for cardiac death and nonfatal MI only
ontaining three variables (SSS, age, and history of MI), the
enefits of 10 events per variable are almost achieved. With
he adjusted model for total cardiac events containing four
ariables and more than 10 events per variable, the results
re more powerful. Post-hoc sample size calculations for the
djusted models for total events and hard events showed the
ower to be 83% and 64%, respectively. Statistically signif-
cant differences in the event-free survival (for both total
vents and hard events) were observed in the current study.
owever, an adjusted model approach for hard events in
uture studies may require a larger sample size.
In the current study, 8.3% of patients were lost toollow-up. This is somewhat higher than some but is similar
t
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Prognostic Value of 82Rb PET September 5, 2006:1029–39o other previous reports, with rates ranging from 3.8% to
.0% (3,21,32,45). This may in part be related to the timing
f follow-up, which was longer than in most previous
PECT studies, and to the fact that some of our patients are
eferred from other centers and regions, which can some-
imes make follow-up more difficult. Although it is not
ossible to determine whether events occurred or not, the
imilarity with the main population suggests that there was
o bias of demographic or SSS among the patients who
ere lost to follow-up.
Recently, electrocardiogram gated acquisition has been
pplied to PET MPI; this as well as left ventricular mass
nd flow measurements may add value to PET imaging
ata. However, measurement of left ventricular mass, flow
uantification, and gated acquisition were not routinely
erformed when these patients underwent their PET im-
ging in the year 2000. Thus data on these parameters are
ot available.
The SPECT subgroup was a selective population; there-
ore, the data must be interpreted with caution. The sample
ize was small but still large enough to show a significant
ifference in total cardiac event rates for normal compared
ith abnormal 82Rb PET MPI. Post-hoc sample size
alculations showed a power 80% with the univariable
nadjusted survival analysis log rank test for this compari-
on. The small number of events in this subgroup limited
he ability to perform the multivariable analysis. Events in
his subset were predominantly revascularization or hospi-
alization. Berman et al. (21) reported that increased total
ardiac events among patients with equivocal SPECT were
lso predominantly revascularizations. Further study with a
arger sample size is required in this population.
The sample size for the obese subgroup was also small.
owever, post-hoc sample size calculations also showed a
ower 80% with the univariable unadjusted survival anal-
sis. Although, the present data show significant differences
n hard and total cardiac event rates for normal compared
ith abnormal 82Rb PET MPI, further studies are required
ith a larger cohorts to confirm our results.
onclusions. The 82Rb PET MPI has significant prog-
ostic value for predicting cardiac events. Normal-perfusion
ET carries an excellent prognosis. With the adjusted
urvival model, 82Rb PET SSS was the strongest predictor
f total cardiac events and was also a significant predictor of
ard cardiac events. The 82Rb PET MPI also seems to have
rognostic value in patients whose diagnosis remains uncer-
ain after SPECT MPI and in patients with obesity. The
rognostic value of PET MPI may improve the manage-
ent of cardiac patients.
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